

Divi's Laboratories

Estimate change



TP change



Rating change



Bloomberg	DIVI IN
Equity Shares (m)	265
M.Cap.(INRb)/(USDb)	2138.6 / 22.4
52-Week Range (INR)	8090 / 5637
1, 6, 12 Rel. Per (%)	20/37/24
12M Avg Val (INR M)	2569

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	105.6	122.6	144.6
EBITDA	34.4	45.6	51.8
Adj. PAT	24.6	32.2	36.2
EBIT Margin (%)	28.2	32.5	31.5
Cons. Adj. EPS (INR)	92.8	121.4	136.4
EPS Gr. (%)	14.3	30.7	12.4
BV/Sh. (INR)	631.4	716.3	811.5

Ratios

Net D:E	-0.2	-0.2	-0.1
RoE (%)	15.5	18.0	17.9
RoCE (%)	15.6	18.1	17.9
Payout (%)	29.7	30.1	30.2

Valuations

P/E (x)	86.8	66.4	59.1
EV/EBITDA (x)	61.2	46.2	40.7
Div. Yield (%)	0.3	0.4	0.4
FCF Yield (%)	0.2	0.4	0.8
EV/Sales (x)	19.9	17.2	14.6

Shareholding pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	51.9	51.9	51.9
DII	19.4	19.2	19.1
FII	20.2	20.3	19.7
Others	8.5	8.6	9.3

FII includes depository receipts

CMP: INR8,056

TP: INR7,720 (-4%)

Neutral

CDMO execution drives earnings beat

Capacity additions and peptide pipeline progress strengthen the long-term growth outlook

- Divi's Lab (DIVI) delivered higher-than-estimated financial performance for 1QFY27, with a 12%/40%/37% beat on revenue/EBITDA/PAT. Strong traction in the custom synthesis business led to an earnings surprise for the quarter.
- DIVI achieved the highest gross margin in the past 20 quarters. The segmental mix and currency tailwinds led to improved profitability during the quarter.
- Certain projects involving major capex are nearing completion, following which the company will undertake qualification and validation batch manufacturing.
- Moreover, peptide-related business remains a strategic growth driver for DIVI, with customer projects progressing as planned across solid-phase and liquid-phase production.
- The company also supplied iodine-based contrast media products during the quarter, with volumes expected to scale up in the coming quarters.
- We raise our earnings estimate by 11%/5% for FY27/FY28, factoring in: a) scale-up in CDMO contracts, b) progression of certain capital expenditure towards commercial manufacturing, c) considerable volatility in certain raw materials/solvents prices due to geopolitical turmoil, and d) improved off-take of Nutraceuticals. We value DIVI at 55x 12M forward earnings to arrive at a TP of INR7,720.
- DIVI is well-positioned to benefit from CDMO demand tailwinds, supported by continuous upgrade of its technology offerings and ongoing capacity additions. Further, the company's consistent efforts to ensure the seamless supply of goods despite geopolitical issues have strengthened its long-term relationships with large innovator customers.
- We build in a 21% earnings CAGR over FY26-28. Given the limited upside from current valuations, we reiterate our Neutral rating on the stock.

Strong earnings outperformance led by mix-driven margin expansion

- DIVI's revenue grew 27.8% YoY to INR30.8b (our est: INR27.6b) for 1QFY27.
- Gross margin expanded 770bp YoY to 68%.
- EBITDA margin expanded 1,050bp YoY to 40.7% (our est: 32.4%), majorly due to a superior product mix as well as operational leverage.
- EBITDA grew 72.2% YoY to INR12.6b (our est: INR8.9b) for 1QFY27.
- PAT grew 74.8% YoY to INR9.0b (our est: INR6.6b).

Research Analyst: Tushar Manudhane (Tushar.Manudhane@MotilalOswal.com) | **Vipul Mehta** (Vipul.Mehta@MotilalOswal.com)

Research Analyst: Eshita Jain (Eshita.Jain@MotilalOswal.com) | **Khyati Sonthalia** (Khyati.Sonthalia@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- The generics:CS ratio in 1QFY27 revenue was 40:60. This implies 45% YoY growth in CS revenue and 6% YoY growth in generics revenue in 1QFY27. Divi garnered INR3b revenue in the nutraceutical business (+19% YoY).
- 1QFY27 CS revenue was driven by supplying validation batches for certain projects.
- DIVI has initiated supplies to one customer for-iodine based products (Contrast media), while supply to another customer is expected to begin in a few months.
- Three major capex programs are nearing completion, with ~70% (~INR20b) of the planned investment incurred to date.
- DIVI indicated a considerable increase in freight costs (both sea and air). In addition, the availability of containers requires careful planning and coordination to avoid delays.
- Accordingly, DIVI is building a strategic inventory buffer to ensure material availability. It is also continuously engaging with customers to evaluate commercially appropriate steps to address the increased costs.
- Management reiterated its guidance of double-digit revenue growth for FY27 but stated that quarterly performance could remain lumpy depending on the timing of customer validations, regulatory approvals, and the custom synthesis/generics mix.
- Management indicated that the FY27 gross margin is expected to be comparable to or slightly higher than FY26, while EBITDA margin is likely to remain similar to last year. This is subject to raw material cost fluctuations, currency tailwinds, and the segment mix.
- The Kakinada facility is currently being used for backward integration and pre-chemistry work to support innovator and generic projects. Management plans to obtain regulatory approvals for the facility over time, following which it will manufacture regulated products. Regulatory approvals are expected to take 1-2 years after project validation.
- Qualification and validation activities for several peptide fragments are expected over the coming quarters, alongside capacity expansion in solid-phase and liquid-phase peptide synthesis.
- The company has filed four peptide DMFs.
- Capacity utilization across the three manufacturing units stood at ~85%.
- Exports constituted ~90% of standalone revenue, with Europe and North America contributing 75% of exports.
- Assets worth INR4.5b were capitalized during the quarter, while capital work-in-progress stood at INR20.3b as of Jun'26.
- Inventory increased ~INR5b QoQ to INR44b.

Quarterly Performance

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var.
(INRm)	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	(%)
Net Sales	24,100	27,150	26,040	28,310	30,800	29,917	30,061	31,803	1,05,600	1,22,581	27,595	11.6
YoY Change (%)	13.8	16.1	12.3	9.5	27.8	10.2	15.4	12.3	12.8	16.1	14.5	
Total Expenditure	16,810	18,270	17,140	18,970	18,250	19,207	19,179	20,322	71,190	76,958	18,655	
EBITDA	7,290	8,880	8,900	9,340	12,550	10,710	10,882	11,481	34,410	45,623	8,941	40.4
YoY Change (%)	17.2	24.0	19.8	5.4	72.2	20.6	22.3	22.9	16.0	32.6	22.6	
Margins (%)	30.2	32.7	34.2	33.0	40.7	35.8	36.2	36.1	32.6	37.2	32.4	
Depreciation	1,120	1,130	1,180	1,200	1,330	1,433	1,439	1,523	4,630	5,725	1,106	
YoY Change (%)	17.5	25.6	19.9	4.5	81.8	19.7	22.3	22.3	16.1	34.0	27.0	
Interest	30	80	60	60	60	40	35	45	230	180	45	
Other Income	800	820	690	650	640	627	648	697	2,960	2,611	697	
PBT before EO Income	6,940	8,490	8,350	8,730	11,800	9,865	10,055	10,609	32,510	42,330	8,486	
EO and Forex Gain/(Loss)	390	630	-550	900	0	0	0	0	1,370	0	0	
PBT	7,330	9,120	7,800	9,630	11,800	9,865	10,055	10,609	33,880	42,330	8,486	
Rate (%)	25.6	24.5	25.3	22.0	23.6	23.6	23.6	23.6	24.2	23.9	22.5	
PAT	5,450	6,890	5,830	7,510	9,020	7,537	7,682	8,106	25,680	32,215	6,577	
Adj. PAT	5,160	6,414	6,241	6,808	9,020	7,537	7,682	8,106	24,623	32,345	6,577	37.1
YoY Change (%)	20.2	30.8	7.4	4.0	74.8	17.5	23.1	19.1	14.3	31.4	27.5	
Margins (%)	22.6	25.4	22.4	26.5	29.3	25.2	25.6	25.5	24.3	26.3	23.8	
Adj. EPS	19.4	24.2	23.5	25.6	34.0	28.4	28.9	30.5	92.8	121.8	24.8	

Quarterly Performance

Y/E March	FY26				FY27E				FY26	FY27E
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE		
Cost Break-up										
RM Cost (% of Sales)	39.7	39.5	36.3	39.5	32.0	36.0	35.5	35.7	38.8	34.8
Staff Cost (% of Sales)	14.1	13.0	14.1	13.5	13.2	13.2	13.4	13.4	13.7	13.3
Other Expenses(% of Sales)	16.0	14.7	15.4	14.0	14.0	15.0	14.9	14.8	15.0	14.7
Tax rate (%)	25.6	24.5	25.3	22.0	23.6	23.6	23.6	23.6	24.2	25.0
Gross Margins(%)	60.3	60.5	63.7	60.5	68.0	64.0	64.5	64.3	61.2	65.2
EBITDA Margins(%)	30.2	32.7	34.2	33.0	40.7	35.8	36.2	36.1	32.6	37.2
EBIT Margins(%)	25.6	28.5	29.6	28.8	36.4	31.0	31.4	31.3	28.2	32.5

Capacity expansion and project pipeline to drive next growth phase

CS: Diversified commercialization pipeline to sustain the growth phase

- Custom synthesis remained the largest business segment in 1QFY27, contributing 60% of total revenue, and grew 45% YoY to INR18.5b, driven by broad-based execution across innovator programs spanning clinical development, validation and commercial supply preparations.
- The custom synthesis pipeline remains healthy, with multiple projects advancing across the clinical, validation, and commercialization stages, while the company continues to focus on timely execution and strengthening infrastructure to support future commercial requirements. The three major capex programs are nearing completion and advancing to the qualification and validation stages.
- Peptides remain a key strategic focus, with several peptide fragments progressing through qualification and validation, alongside capacity expansion in solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS).
- The company continues to strengthen its process development, analytical, and manufacturing capabilities, while expanding advanced technologies such as continuous-flow chemistry, biocatalysis, and process intensification to support increasingly complex customer requirements.
- Unit III is playing an increasingly important role through backward integration and pre-chemistry operations, improving network flexibility, supply assurance, and capacity utilization across existing facilities while progressing toward future regulatory qualification.
- We expect custom synthesis to remain the key growth driver with a CAGR of 20% over FY26-28, supported by commercialization of dedicated capex projects, continued expansion in peptide CDMO, increasing contribution from late-stage innovator programs, and sustained investments in manufacturing capabilities.

Generics: Resilient base with multiple growth levers

- Generics contributed 40% of 1QFY27 revenue and grew 8.8% YoY to INR12.3b, with stable volumes despite continued pricing pressure across products and geographies.
- Backward integration into key starting materials and intermediates continues to enhance supply assurance, improve manufacturing efficiency, and support margins amid volatile raw material markets.
- Nutraceuticals continued to perform well, with revenue increasing to INR3.0b (vs INR2.5b in 1QFY26), reflecting sustained demand across global markets.
- The nutraceutical portfolio has expanded from just two products 20 years ago to over 100 offerings across human health, animal health, and dietary supplements, with the company continuing to invest in capabilities and capacity to support future growth.
- Contrast media is emerging as an incremental growth opportunity, with the commercialization of iodine-based products already underway with one customer and supplies to another customer expected to commence over the coming months. Gadolinium programs continue to progress through clinical qualification stages.
- We expect the generics business to deliver a CAGR of 13% over FY26-28, supported by commercialization of new API opportunities, continued expansion

in nutraceuticals, ramp-up of contrast media products, and benefits from deeper backward integration and manufacturing efficiencies.

Reiterate Neutral

- We raise our earnings estimate by 11%/5% for FY27/FY28, factoring in: a) a scale-up in CDMO contracts, b) progression of certain capital expenditure towards commercial manufacturing, c) considerable volatility in certain raw materials/solvents prices due to geopolitical turmoil, and d) improved off-take of Nutraceuticals. We value DIVI at 55x 12M forward earnings to arrive at a TP of INR7,720.
- DIVI is well-positioned to benefit from CDMO demand tailwinds on the back of continuous upgrade of technology offerings as well as capacity additions. Further, consistent efforts toward seamless supply of goods despite geopolitical issues strengthen long-term relationships with large innovator customers.
- We build in a 21% earnings CAGR over FY26-28. Considering the valuation provides limited upside from current levels, we reiterate our Neutral rating on the stock.

Story in charts

Exhibit 1: Revenue grew 27.8% YoY in 1QFY27




Exhibit 2: The CS segment contributed 60% to revenue




Exhibit 3: Gross margin expanded 770bp YoY in 1QFY27




Exhibit 4: EBITDA margin expanded 1,050bp YoY




Exhibit 5: Expect ~17% revenue CAGR over FY25-28




Exhibit 6: Expect margin to expand 320bp over FY26-28






Exhibit 7: Expect ~21% earnings CAGR over FY26-28



Source: Company, MOFSL

Exhibit 8: RoCE to reach ~17.9% by FY28



Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	89,598	77,675	78,450	93,600	1,05,600	1,22,581	1,44,634
Change (%)	28.6	-13.3	1.0	19.3	12.8	16.1	18.0
Total Expenditure	50,779	53,997	56,220	63,930	71,190	76,958	92,794
% of Sales	56.7	69.5	71.7	68.3	67.4	62.8	64.2
EBITDA	38,819	23,678	22,230	29,670	34,410	45,623	51,839
Margin (%)	43.3	30.5	28.3	31.7	32.6	37.2	35.8
Depreciation	3,115	3,432	3,780	4,020	4,630	5,725	6,241
EBIT	35,704	20,246	18,450	25,650	29,780	39,898	45,598
Int. and Finance Charges	8	7	30	10	230	180	164
Other Income	733	2,150	3,100	3,030	2,960	2,611	2,200
PBT bef. EO Exp.	36,429	22,390	21,520	28,670	32,510	42,330	47,635
EO Items	406	1,297	140	500	1,370	0	0
PBT after EO Exp.	36,835	23,687	21,660	29,170	33,880	42,330	47,635
Total Tax	7,231	5,453	5,630	7,250	8,200	10,115	11,432
Tax Rate (%)	19.6	23.0	26.0	24.9	24.2	23.9	24.0
Minority Interest	0	0	0	0	0	0	0
Reported PAT	29,605	18,234	16,027	21,920	25,680	32,215	36,202
Adjusted PAT	29,303	17,222	15,926	21,552	24,642	32,215	36,202
Change (%)	46.1	-41.2	-7.5	35.3	14.3	30.7	12.4
Margin (%)	32.4	21.6	20.3	23.0	23.3	26.3	25.0

Balance Sheet							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	531	531	531	531	530	530	530
Total Reserves	1,16,751	1,27,140	1,35,180	1,49,160	1,67,080	1,89,608	2,14,880
Net Worth	1,17,282	1,27,671	1,35,711	1,49,691	1,67,610	1,90,138	2,15,410
Deferred Tax Liabilities	4,069	5,230	5,720	5,090	4,690	4,690	4,690
Capital Employed	1,21,351	1,32,901	1,41,431	1,54,781	1,72,300	1,94,828	2,20,100
Gross Block	56,246	63,653	67,597	78,647	94,137	1,21,041	1,43,422
Less: Accum. Deprn.	12,995	16,427	20,207	24,227	28,857	34,582	40,823
Net Fixed Assets	43,251	47,226	47,390	54,420	65,280	86,459	1,02,599
Capital WIP	4,699	2,119	7,780	10,220	21,130	14,226	13,845
Total Investments	720	771	820	650	690	690	690
Curr. Assets, Loans&Adv.	84,933	94,130	99,011	1,04,030	1,13,230	1,25,005	1,40,533
Inventory	28,286	30,004	31,840	32,360	39,540	46,385	53,389
Account Receivables	24,239	17,925	21,560	27,310	29,840	36,606	43,192
Cash and Bank Balance	28,189	42,131	39,800	37,150	34,140	30,742	30,653
Loans and Advances	4,219	4,070	5,811	7,210	9,710	11,271	13,299
Curr. Liability & Prov.	12,251	11,345	13,570	14,539	28,030	31,552	37,567
Account Payables	7,957	7,625	8,640	9,100	12,110	13,072	15,762
Other Current Liabilities	3,986	3,364	4,490	4,899	14,510	16,843	19,873
Provisions	309	355	440	540	1,410	1,637	1,931
Net Current Assets	72,681	82,785	85,441	89,491	85,200	93,453	1,02,966
Appl. of Funds	1,21,351	1,32,901	1,41,431	1,54,781	1,72,300	1,94,828	2,20,100

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)							
EPS	110.4	64.9	60.0	81.2	92.8	121.4	136.4
Cash EPS	122.1	77.8	74.2	96.3	110.3	142.9	159.9
BV/Share	441.8	481.0	511.2	563.9	631.4	716.3	811.5
DPS	29.9	17.0	15.5	21.2	23.9	30.3	34.1
Payout (%)	32.3	29.8	31.0	31.0	29.7	30.1	30.2
Valuation (x)							
P/E	73.0	124.2	134.3	99.2	86.8	66.4	59.1
Cash P/E	66.0	103.6	108.5	83.6	73.1	56.4	50.4
P/BV	18.2	16.8	15.8	14.3	12.8	11.2	9.9
EV/Sales	23.6	27.0	26.8	22.5	19.9	17.2	14.6
EV/EBITDA	54.4	88.5	94.4	70.8	61.2	46.2	40.7
Dividend Yield (%)	0.4	0.2	0.2	0.3	0.3	0.4	0.4
FCF per share	45.2	69.8	8.1	10.3	9.3	14.5	33.2
Return Ratios (%)							
RoE	27.9	14.1	12.1	15.1	15.5	18.0	17.9
RoCE	27.9	14.1	12.1	15.1	15.6	18.1	17.9
RoIC	36.9	17.7	15.1	19.3	20.2	22.9	21.4
Working Capital Ratios							
Asset Turnover (x)	1.6	1.2	1.2	1.2	1.1	0.6	0.7
Inventory (Days)	115	141	148	126	137	138	135
Debtor (Days)	99	84	100	106	103	109	109
Creditor (Days)	32	36	40	35	42	39	40
Leverage Ratio (x)							
Net Debt/Equity	-0.25	-0.34	-0.3	-0.3	-0.2	-0.2	-0.1

Cash Flow Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	36,835	23,687	21,660	29,170	33,880	42,330	47,635
Depreciation	3,115	3,432	3,780	4,020	4,630	5,725	6,241
Interest & Finance Charges	4	-2,144	-3,070	-3,020	-2,730	-2,431	-2,036
Direct Taxes Paid	-6,410	-5,453	-5,630	-7,250	-8,200	-10,115	-11,432
(Inc)/Dec in WC	-13,705	3,838	-4,987	-6,700	1,281	-11,651	-9,602
CF from Operations	19,840	23,360	11,753	16,220	28,861	23,857	30,805
Others	-722	0	0	0	0	0	0
CF from Operating incl EO	19,118	23,360	11,753	16,220	28,861	23,857	30,805
(Inc)/Dec in FA	-7,132	-4,827	-9,605	-13,490	-26,400	-20,000	-22,000
Free Cash Flow	11,986	18,534	2,148	2,730	2,461	3,857	8,805
(Pur)/Sale of Investments	-15,990	-50	-50	170	-40	0	0
Others	1,173	2,150	704	3,030	2,960	2,611	2,200
CF from Investments	-21,949	-2,727	-8,951	-10,290	-23,480	-17,389	-19,800
Issue of Shares	0	0	0	0	-1	0	0
Inc/(Dec) in Debt	-4	0	0	0	0	0	0
Interest Paid	-4	-7	-30	-10	-230	-180	-164
Dividend Paid	-5,309	-5,432	-4,968	-6,794	-7,637	-9,687	-10,930
Others	13,992	-1,043	-135	-1,777	-522	0	0
CF from Fin. Activity	8,676	-6,481	-5,133	-8,581	-8,390	-9,867	-11,094
Inc/Dec of Cash	5,844	14,152	-2,331	-2,651	-3,009	-3,398	-89
Opening Balance	21,560	28,189	42,131	39,800	37,150	34,140	30,742
Closing Balance	27,405	42,341	39,800	37,150	34,140	30,742	30,653
Forex and other adjustments	784	-210	0	0	0	0	0
Total Cash & Cash Eq	28,189	42,131	39,800	37,150	34,140	30,742	30,653

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
- Analyst Certification**
- The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.